The Ellipta® in asthma and chronic obstructive pulmonary disease:device characteristics and patient acceptability by Jones, Thomas L. et al.




Thomas L Jones*, Daniel M Neville*, Anoop J Chauhan 
Department of Research and Innovation, Portsmouth Hospitals NHS Trust, Portsmouth, UK 
* - Joint First authors 
 
Corresponding author: 
Dr Thomas Jones, 
Department of Research and Innovation 





+44 (0) 2392 286 000 ext 5154 
  
Abstract 
Asthma and COPD are primarily treated with inhaled medication, but delivery of that medication to 
its site of action is problematic; patients’ ability to use inhalers will affect therapeutic response. 
Multiple inhaler devices are available but they are variably easy to use with consequent effects on 
compliance, intentional or otherwise. The Ellipta device is a novel blister-strip dry powder inhaler 
with medium resistance and a consistent delivered dose across a range of inspiratory flow rates. The 
Ellipta has proven easy to use and is preferred by patients across several evaluations and compared 
to other inhaler devices. The Ellipta is used to administer multiple inhaled medications, all in single-




Asthma and Chronic Obstructive Pulmonary Disease (COPD) are common airway diseases that result 
in significant morbidity and mortality worldwide. Asthma affects approximately 340 million 
people[1], resulting in 420,000 deaths in 2016 and 23.7m Disability Adjusted Life Years (DALYs). 
COPD is the fourth leading cause of death worldwide, accounting for 2.9m deaths in 2016 and 63.4m 
DALYs[1]. Around 65 million people suffer with moderate to severe COPD[2] which causes significant 
morbidity and economic burden on top of the effect on mortality[3]. Both conditions are 
characterised by airway inflammation, airway narrowing and consequent increased respiratory 
effort. 
As conditions of airway inflammation, both asthma and COPD are treated by administration of 
inhaled medication in order to directly target the site of pathology[3,4]. Current international 
guidelines place inhaled corticosteroids at the forefront of the therapeutic armamentarium for 
asthma.  COPD is treated primarily by bronchodilation with long acting beta agonists and muscarinic 
antagonists but both anti-inflammatory and bronchodilator treatments are used for both conditions. 
Oral therapies including oral corticosteroids and xanthines are used, but are primarily restricted to 
severe or acute disease due to systemic side effects of most per oram therapy. 
The mechanics of delivery of inhaled therapy remains a significant challenge in the respiratory field. 
Devices and systems must be able to deliver relevant medications, alone or in combination, via the 
variable anatomy of the upper and lower respiratory tract, to the bronchial epithelium. This must be 
done in as uniform a manner as possible, whilst avoiding deposition in the upper respiratory tract to 
limit side effects and systemic absorption. Simultaneously, devices must be easy and pleasant to use, 
otherwise patients will not use them however optimal their delivery characteristics. Published data 
demonstrates 31% of patients have correct inhaler technique and this has not improved over 
time[5], perhaps because healthcare professionals inhaler technique can be equally poor[6]. 
Pressurised metered dose inhalers were first introduced in 1956[7] followed by dry powder inhalers 
in the late 1960s. Types of DPI have changed significantly since they were first introduced in order to 
optimise drug delivery and ease of use. Currently available DPIs vary significantly in design features 
and usability characteristics. In this article we aim to review the Ellipta® device in terms of device 
elements and patient usage. 
 The Ellipta device 
Design features 
The Ellipta is a breath-actuated blister strip dry powder inhaler, produced by GlaxoSmithKline plc. 
(Brentford, UK). The Ellipta device is currently used to deliver Fluticasone Fuorate (FF), Vilanterol (VI) 
and Umeclidinium (UMEC) in the following preparations: as FF alone (Arnuity®[8]), FF/VI 
(Relvar®/Revinty®/Breo®[9]), VI/UMEC (Anoro®[10]) and as UMEC alone (Incruse®[11]). 
Combinations of all three compounds within a single device are currently being tested with results to 
date being positive[12]. The combination inhalers contain separate blister strips for each 
medication, with parallel opening of blisters with a single priming action. The Ellipta device provides 
30 doses in a single-use device. All preparations are intended for once daily administration, and 
therefore each device contains 30 days treatment[9–11]. The Ellipta device is licensed for use in 
people 12 years of age and over. There is no data available for its safe use in a paediatric population.  
Actuation of the Ellipta device is kept simple with a three step actuation procedure: open the cover, 
inhale from the mouthpiece and re-close the cover. The device is primed by the opening of the lid, 
which uncovers the mouthpiece and the device is breath-actuated [13]. The simplicity of use belies a 
carefully engineered mechanism (figure 1) capable of reliable actuation at low flow rates . The 
device features a dose counter on the front surface to assist the patient with device replacement 
once empty. The counter is partly red once fewer than ten doses remain, and entirely red if it is 
primed after the final dose has been actuated. If a user primes the device by opening the lid (figure 
2) and closes it again without inhaling then the dose is lost. The Ellipta® is a single use device, 
requires no cleaning and can be disposed of or recycled by pharmacies after use. 
 
Figure 1. Internal structure of the Ellipta device. Image by Warwick Design Consultancy. Image ©GSK 
 
Specification 
Aerosolisation of the contents of any DPI is dependent on sufficient flow being produced through 
the device. This is dependent on the patient generating a drop in pressure at the mouthpiece and 
the internal resistance of the inhaler. The Ellipta device is designed with a moderate resistance to 
patient inspiratory effort and has a typical specific resistance of 0.027 kPa0.5(L/min)-1 [14], resulting in 
a 3kPa pressure drop giving flow of 60L/min[13], and a 4.0kPa pressure drop giving flow of 
74L/min[14].Table 1 compares device resistances between the Ellipta and other DPIs. The inspiratory 
flow rate is an important inhalation profile parameter because of its direct influence on the dose 
delivery from most DPIs. The Ellipta device produces consistent dose delivery at flow rates over 
30L/min[13,15] and this covers the inhalation rates across asthma and COPD disease severity, with 
even patients who suffer from very severe COPD able to generate an inspiratory effort of 41.6L/min 
whilst using the inhaler[15,16].  
Table 1. Comparison of characteristics of DPI devices. 
 










Breezhaler 0.017 111 Capsule N/A COPD 
Ellipta 0.027 74 Prefilled Yes Asthma, COPD 
Accuhaler 0.027 72 Prefilled Yes Asthma, COPD 
Genuair 0.031 64 Prefilled Yes COPD 
NEXThaler 0.036 54 Prefilled Yes Asthma, COPD 
Turbohaler 
Pulmicort 
0.039 54 Prefilled Yes Asthma, COPD 





The particle size and fine particle fraction of the Ellipta inhalers vary by the medication delivered. 
Analysis using a next-generation impactor (NGI) at flow rates of 60L/min, the mean delivered dose 
(as % of the prescribed dose/blister content) is 81-94%. This drops to 71-97% when flow rates vary 
between 30-90L/min. The mean delivered dose increases with higher flow rates due to improved 
deagglomeration of the powdered medication. Mean fine particle mass (<5µm) at 60L/min varied 
between 18.5% to 34.4% of blister content in ambient conditions[13]. 
In vitro evaluation of drug delivery using patient inhalation profiles captured in vivo demonstrates 
mean delivery of 77-90% of the blister content depending on the device contents[15]. This results in 
a pulmonary fraction (Ex-throat dose) of 22.0-42.5% and a fine particle dose of 18.8-37.2%, again 
depending on blister contents. 
 Figure 2. Priming and actuation of the Ellipta device, showing the key external features (Note a 
change in orientation does not affect device function). Image ©GSK. 
 
Ellipta and patients with airway disease 
Optimising treatment effectiveness requires tailoring the drug-device combination for each 
individual patient, based on his/her individual characteristics, the disease and its severity, the 
characteristics of the device, and the skills of involved healthcare professionals. When prescribing 
any inhaled medication for the treatment of asthma and COPD, ease-of-use, patient preference and 
their satisfaction with the device must be taken into account. Studies have shown that adherence to 
inhaled therapies is generally poor[17] and this has been associated with complicated inhaler 
regimens, misplaced beliefs around side effects and a poor experience in using the device[18,19]. As 
a consequence the choice of inhaler should be, in part, based on ease-of-use and patient satisfaction 
as this can influence a person’s adherence to their treatment and thus potentially alter their long-
term outcome[18,19]. Furthermore correct inhaler technique is vital for efficient drug delivery. 
Tailored patient training, by a healthcare professional, is recommended by international guidelines 
for asthma and COPD management[3,4]. Critical inhaler errors can be defined as those that 
significantly impact the effectiveness of the drug delivery to the airways, for example failing to open 
the cover of the device, or exhaling directly into the mouthpiece. Without training and education, 
critical inhaler errors (which significantly impact the effectiveness of drug delivery) occur commonly 
in both asthma and COPD[20,21]. 
 
Critical errors, time needed for instruction, ease-of-use and patient preference for Ellipta 
Critical errors, time needed for instruction, ease-of-use and patient preference have recently been 
assessed in a randomised, open-label, multicentre crossover study in 729 patients with asthma or 
COPD[22]. Inhaler naïve patients were assigned to inhale Ellipta vs Diskus, metered dose inhaler 
(MDI), Turbuhaler, Handihaler or Breezhaler. Patients were required to read the Patient Information 
Leaflet (PIL) before using the device with no other training. Critical errors were recorded by trained 
respiratory nurses. In addition, the subsequent number of instructions required before correct 
technique was observed, alongside ease-of-use rating and inhaler preference was reported. Critical 
errors were made by significantly fewer COPD patients using the Ellipta inhaler compared with all 5 
other inhalers (p<0.001, Figure 3). Significantly fewer asthma patients made a critical error when 
using the Ellipta inhaler compared with the Turbuhaler (p<0.001), with non-significant differences 
with MDI and Accuhaler (p=0.074). Furthermore the majority of asthma and COPD patients made no 
errors using the Ellipta inhaler after only reading the PIL. Whereas the majority of patients required 
nurse instruction and training for the other inhalers before a correct technique was witnessed. In 
both asthma and COPD populations patients reported a significantly high ease-of-use rating 
compared with that for the other inhalers (very easy or easy to use; p<0.001). The Ellipta inhaler was 
also significantly preferred by a majority of patients compared with all other comparator devices 
(p<0.001, Figure 4), with specific preference for the time taken to use, dose counter, comfort of the 
mouthpiece and ease of opening highlighted. The study protocol minimised bias for patient 
preference reporting by using standardised, uniform questionnaire assessments completed by 
patients after finishing all inhaler procedures. By also being performed across multiple centres the 
results reflect the opinions of a diverse population.  
 
Figure 3. Percentage of patients with A – COPD, or B – Asthma making at least one critical error after 
reading the patient information leaflet. Reproduced from reference[22] 
 
Patient preference has also been explored in a head-to-head, phase IIIb, randomised, open-label, 
crossover study between placebo Ellipta and Diskus DPI inhalers[23]. 287 COPD patients were 
randomised to either an Ellipta once daily or a Diskus twice daily inhaler regime for 1 week before 
crossover. Inhaler preference was explored based on dose-counter size, inhaler size, number of 
steps needed, comfort of mouthpiece, ease of opening and dosing regimen preference. A 
significantly larger proportion of patients preferred the Ellipta inhaler over the Diskus for each of the 
selected attributes (all p<0.001). Preference was highest for the dose-counter size (68% vs 20%), 
number of steps needed to use the inhaler (67% vs 23%) and for the once daily dosing regimen (67% 
vs 23%).  
 
Figure 4. Device preferences reported by Van der Palen et al in A - COPD and B – Asthma. 
Reproduced from reference[22] 
 
Qualitative assessment through the use of semi-structured interviews has been performed on 75 
patients with asthma and COPD who had recently completed a phase IIIa clinical trial of the Ellipta 
inhaler[24] . Participants were asked about their satisfaction of the device and how they would rate 
the inhaler on a subjective 1-10 scale.  Both asthma and COPD patients reported high levels of 
satisfaction with the Ellipta device, describing it as easy to use due to simple operation steps, good 
usability, clear dose counter and overall device ergonomics. Overall average performance scores 
were greater than 9 out of 10 and again interview participants preferred the Ellipta to other inhaler 
devices.The  Ellipta also performs well in an elderly population, with the vast majority of patient’s ≥ 
65 years of age finding it easy-to-use.[13,25]   
 
Conclusion 
The Ellipta device is a patient friendly, easy-to-use device for delivering once daily dry powder 
therapy for asthma and COPD. It is a medium resistance inhaler that gives a consistent delivered 
dose over a wide range of inspiratory flow rates. The Ellipta compares favourably with other inhaler 
devices due to ease of use, handling and appearance. Simplicity of use for patients allows easier 
education by healthcare professions and greater confidence in reliable delivery of therapeutic 
compounds. It is an additional option in the complex decision making process in choosing the right 
inhaler device for the right patient.  
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